At last, something I own (other than Biota - praise the lord and asian bird flu) going up. The company looks very solid and the price is still ata discount to value ... er ... in my opinion.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%